ARTICLE | Emerging Company Profile
Hercules' IDO alternative
Why Hercules thinks AHR inhibitors could improve on IDO/TDO inhibitors
February 29, 2016 8:00 AM UTC
Hercules Pharmaceuticals B.V. is developing an inhibitor of aryl hydrocarbon receptor that taps into the same pathway as IDO and TDO inhibitors but could improve upon their tolerability while delivering similar efficacy. Improved tolerability could be a benefit when used in combination with other immunotherapies.
According to CEO Bart Wuurman, aryl hydrocarbon receptor (AHR) is a key component of the tryptophan metabolism signaling pathway, which includes indoleamine 2,3-dioxygenase (INDO; IDO) and tryptophan 2,3-dioxygenase (TDO2; TDO)...